# Exelixis, Inc. – Consensus ‘buy’ rating and 25.1% Upside Potential

- Link: https://www.directorstalkinterviews.com/exelixis-inc.consensus-buy-rating-and-25.1-upside-potential/4121131742
- Published: 2023-11-01T14:35:22+00:00
- Author: Charlotte Edwards

**Exelixis, Inc.** which can be found using ticker (EXEL) have now 17 confirmed 
analysts covering the stock with the consensus suggesting a rating of ‘buy’. The
range between the high target price and low target price is between $32.00 and $
18.00 and has a mean target at $25.76. Given that the stocks previous close was 
at $20.59 this now indicates there is a potential upside of 25.1%. There is a 50
day moving average of $21.61 and the 200 day MA is $19.53. The company has a market
cap of 6.62B. The stock price for the company is currently $20.80 USD

 The potential market cap would be $8,285,141,914 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 41.6, revenue per share of $5.30
and a 2.93% return on assets.

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines
and combination regimens at the forefront of cancer care. It has four products, 
including its flagship molecule, cabozantinib, which is an inhibitor of multiple
tyrosine kinases, including MET, AXL, VEGF receptors and RET. Cabozantinib is approved
as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and
in combination with Bristol-Myers Squibb Company’s (BMS) OPDIVO (nivolumab), for
hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated
thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic
medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor
of MEK approved as part of multiple combination regimens to treat specific forms
of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the
mineralocorticoid receptor (MR) approved the treatment of hypertension.

Share on: